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Abstract
Colorectal cancer (CRC) remains one of the most common malignancies and the second
leading cause of cancer‐related death worldwide; treatment algorithms include surgery,
chemotherapy and targeted therapies.  Immunotherapy has recently emerged as an
effective treatment approach in several types of cancer, including non–small cell lung
cancer, melanoma and kidney cancer. In CRC, novel immune‐checkpoint inhibitors such
as anti‐CTLA4 and PD1/PDL1 monoclonal antibodies have shown limited efficacy,
although ongoing trials in mismatch repair‐deficient CRC have shown significant and
promising results. Here, we review the role of immune‐microenvironment in colorectal
cancer and current clinical data about therapeutic activity of immunotherapy in the
treatment of CRC.
Keywords: colorectal cancer, immunotherapy, drug development, checkpoint inhibi‐
tion, mismatch repair
1. Introduction
Colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of
cancer‐related death worldwide. Surgery, chemotherapy, radiation therapy and targeted agents
including anti‐angiogenic and anti‐epidermal growth factor receptor (EGFR) therapies form
the backbone of treatment for CRC in various stages. Unfortunately, when diagnosed at advanced
stage, CRC is still inevitably fatal. More than 50% of patients diagnosed with CRC eventually
develop metastases, and almost 90% of these patients have unresectable disease [1–3]. In some
patients with metastatic disease, metastectomy is still possible and can result in a cure in
appropriately selected patients [2, 3]. The almost totality of metastatic CRC patients eventual‐
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ly develops resistance to all available standard therapies leading to cancer progression and death
[4].
As we will discuss here, immunotherapy and immunomodulatory drugs may represent future
therapeutic options to be included in the therapeutic armamentarium in the treatment of CRC.
The importance of inflammation in CRC is partially supported by the evidence that patients
with inflammatory bowel diseases, i.e., patients with ulcerative colitis and Crohn's disease are
at increased risk for developing CRC [5]. It is assumed that chronic inflammation is a significant
contributor to cancer development. This is supported by the fact that colon cancer risk increases
with longer duration of colitis, greater anatomic extent of colitis, the concomitant presence of
other inflammatory manifestations like primary sclerosing cholangitis [6] and the fact that
certain drugs used to treat inflammation, such as 5‐aminosalicylates and steroids, may prevent
the development of CRC in this clinical setting [7]. It may be thus possible that by shaping the
immune composition of the CRC microenvironment through novel immunotherapies, this
may ultimately lead to a therapeutic effect in CRC.
2. The immune‐cell microenvironment in colorectal cancer
An important step in tumour progression is the evasion and suppression of the host immune
system [8, 9], as shown in Figure 1. In the normal microenvironment, the effector cells,
including the natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), are capable of
driving potent anti‐tumour suppressive activities. Tumour cells are often able to induce an
Figure 1. Immune‐cell microenvironment in colorectal cancer. The evasion and suppression of the host immune sys‐
tem is an important step of colorectal cancer (CRC) progression. In physiologic conditions, effector cells, including the
natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), exert tumour surveillance and tumour suppressive activi‐
ties. Tumour cells are able to induce an immunosuppressive microenvironment that protects them from the host im‐
mune system through the expansion of regulatory immune cells (i.e., myeloid‐derived suppressor cells (MDSCs) and
regulatory T cells (Tregs)) and alternative activation of other immune cells, including macrophages, granulocytes and
dendritic cells.
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immunosuppressive microenvironment that protects them from the host immune system.
Overall, tumour cells are able to shape the host microenvironment, which is rich of immune
cell populations, in a suitable way for them to survive to the host immune system recognition
[10, 11]. The two major immunosuppressive mechanisms in cancer are (1) expansion of
regulatory immune cells (i.e., myeloid‐derived suppressor cells (MDSCs) and regulatory T
cells (Tregs)) and (2) activation of the inhibitory T‐cell pathways—programmed cell death‐1/
programmed cell death‐ligand 1 pathways (PD‐1/PD‐L1 pathways).
3. Myeloid‐derived suppressor cells
Myeloid‐derived suppressor cells are a heterogeneous and immature subset of circulating cells
of myeloid derivation that can differentiate into, macrophages, granulocytes or dendritic cells
(DCs) under physiologic conditions. However, under pathological conditions such as cancer
or inflammation, the differentiation of these immature myeloid cells is inhibited resulting in
accumulation of MDSCs in the tumour microenvironment or in the sites of inflammation [12].
For example, in cancer patients and tumour models, MDSCs accumulate in the tumour
microenvironment because of the release of soluble factors by tumour cells or by other cells of
the microenvironment, i.e., granulocyte macrophage colony stimulating factor (GM‐CSF),
interleukin‐1 β and stromal‐derived growth factor 1‐α [13, 14]. MDSCs can then suppress T‐
cell proliferation through expression of several immune suppressive factors, including
arginase, reactive oxygen species (ROS) and nitric oxide (NO). MDSCs can also promote the
development of Treg cells in vivo, which are anergic and immune‐suppressive [15]. Several
studies have consistently shown that cancer patients with higher MDSC levels have shorter
survival compared to patients with lower MDSC levels [16, 17]. Moreover, depletion of MDSCs
in tumour‐bearing mice using anti Gr‐1 antibody [18, 19] or MDSC‐targeting specific peptides
have shown anti‐tumour activities [20] suggesting that MDSCs can be a good target for future
anti‐tumour treatments. Two main subsets of MDSCs have been described, namely, granulo‐
cytic MDSC (G‐MDSC) or polymorphonuclear (PMN)‐MDSCs and monocytic MDSC (Mo‐
MDSC). G‐MDSCs have granulocyte‐like morphology characterised by increased levels of ROS
and low levels of NO, whereas Mo‐MDSCs have monocyte‐like morphology with increased
level of NO, but low levels of ROS. Human G‐MDSCs and Mo‐MDSCs are classically defined
as CD11b+ CD33+ HLA‐DR− /lowCD14− and CD11b+ CD33+ HLA‐DR−/low CD14+, respectively. In
tumour‐bearing mice, G‐MDSCs are the major MDSC subset that expands in the peripheral
lymphoid organs after tumour engraftment pointing to a different biology of these cells in
human and mice [21].
MDSCs promote metastasis development and primary tumour growth both in CRC patients
and CRC murine models [22]. Importantly, MDSCs have also been implicated in the resistance
to anti‐angiogenic therapies used for the treatment CRC [23] via their ability to stimulate the
expression of genes, whose products promote leukocyte recruitment, alternative angiogenic
mechanisms, tumour migration, wound healing and formation of premetastatic niches in distal
metastatic organs [23].
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4. Regulatory T cells (Tregs)
Treg cells are a subset of CD4+ T lymphocytes characterised by the expression of Forkhead Box
P3 (FOXP3) transcription factor [24]. Tregs are able to suppress the function of antigen
presenting cells (APCs), i.e., dendritic cells, and effector T cells by direct contact or by release
of anti‐inflammatory cytokines (IL‐10 and TGF‐ β). Tregs are major players in the development
of tumour immunosuppressive microenvironment; these cells accumulate both in the tumour
microenvironment and the peripheral blood of patients with cancer [25, 26]. The increased
frequency of Tregs both in the peripheral blood and especially in the sites of tumour growth
has generally been considered a marker of poor prognosis due to Treg‐mediated suppression
of anti‐tumour immunity [27, 28]. In transgenic mouse models, it has been shown in mice that
Treg depletion induces regression of solid tumours and lymphomas, following increased
intratumoural accumulation of activated CD8+ cytotoxic T cells [29–31]. These data indicate
that targeting Tregs can represent a potential anti‐tumour strategy; however, the development
of autoimmune diseases following administration of Treg cells has been described in these
preclinical studies and may represent a limitation in the pursue of novel anti‐Treg treatments
in patients. In CRC, several studies have shown that Treg density in tumour specimens
represents an independent negative prognostic factor [32–34]. Low‐dose cyclophosphamide
has been shown to reduce the numbers and function of Tregs and to induce anti‐tumour,
immune‐mediated effects [35, 36]; this has been shown to be true in preclinical models of CRC
[37], but no studies have been carried out in CRC patients so far.
5. Dendritic cells
Dendritic cells are cells of bone marrow origin defined as professional antigen presenting cells,
which have the ability to present self and non‐self antigens to T cells, thus promoting immunity
or immune‐tolerance [38]. Antigen presentation by DCs is able to induce naive T cells differ‐
entiation into effector and memory T cells; however, it can also lead to different forms of T‐
cell tolerance, depending on the local microenvironment stimuli and the functional status of
the DCs. Myeloid‐DCs (mDCs) and plasmacytoid‐DCs (pDCs) are two major DC subsets that
have been identified based on their origin, immune‐phenotype and functional status [39]. In
human, mDCs are usually defined as Lin–HLADR+CD11c+CD123dim cells, whereas pDCs are
Lin–CD11c–CD4+CD45RA+CD123+ILT3+. Several studies have documented accumulation of
DCs in tumour sites, which often correlated with poor prognosis [40–42]. The loss of tumour‐
derived antigen presentation ability by tumour‐infiltrating DCs has been shown to be the
consequence of the suppressive effects of the tumour microenvironment mediated by various
cytokines [43]. For example, it has been demonstrated that tumour‐infiltrating pDCs from solid
tumours express high levels of inducible T‐cell co‐stimulator ligand (ICOS‐L), which explains
their ability to induce Tregs proliferation [44, 45], thus leading to local immunosuppression.
Moreover, TGF‐ β secreted by DCs from breast cancer patients is able to induce Treg‐cell
proliferation and accumulation, thus leading to tumour growth [46]. The role of DCs in CRC
has been controversial mostly due to the technical difficulties associated with their quantifi‐
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cation and identification. For these reasons, it is difficult to draw a conclusion about the role
of DCs and performance of DCs as a predictor of outcome for CRC [47, 48].
6. Natural killer cells
NK cells represent a heterogeneous lymphocyte population with direct‐cytotoxic anti‐tumour
capacity and multiple immunoregulatory properties. Natural killer group 2D (NKG2D) is one
of the NK cell activating receptors that recognises various proteins expressed on the surface
of target cells in response to several forms of cellular stress. One of the ligand of NKG2D is the
MHC class I polypeptide‐related sequence A (MICA); target tumour cells that express MICA
are efficiently killed via NKG2D despite the expression of MHC class I molecules, describing
a pathway of anti‐tumour activity mediated by NK cells [49]. Several preclinical studies have
shown the susceptibility of CRC cells to the NK cell–mediated killing [50–52], which can be
enhanced by the contemporary treatment with anti‐CRC drugs like anti‐EGFR inhibitors [53].
Interestingly Gharagozloo et al. [54] have recently shown that metastatic CRC patients present
a significant reduction in the percentage of circulating NKG2D+NK cells as well as NKG2D
mRNA expression in peripheral blood as compared to healthy controls, suggesting a specific
defect of NK cell–mediated natural immunity in CRC patients.
7. Macrophage in colorectal cancer
Cells of the monocyte–macrophage lineage are one of the major components of the leukocyte
infiltration in tumours; there is strong evidence that these cells promote inflammatory circuits
that ultimately lead to tumour progression, tumour cell invasion and metastasis [55].
Macrophages recruited to the tumour‐associated microenvironment may exist both in a
classically activated inflammatory phenotypes (M1) with anti‐tumour capacity or an alterna‐
tively activated, immunosuppressive (M2) phenotype with tumour supporting ability [56];
M1‐polarised macrophage secretes a large amount of IL‐12, IL‐1α, IL‐1β, IL‐6, TNF‐α, nitric
oxide (NO) and ARG1, and stimulate secretion of IFN‐γ by Th1 lymphocytes, thus activating
Th1 immune response which in turn stimulate the tumour specific‐CTL cytotoxicity. However,
during tumour progression, macrophages shift towards a M2‐polarised phenotype induced
by the exposure of these cells to IL‐4, IL‐13, M‐CSF/CSF‐1, IL‐10 and TGF‐β1, among other
factors present in the tumour microenvironment. In this state, macrophages are defined as
tumour‐associated macrophages (TAMs) and are able to support tumour growth, survival and
metastasis. TAMs mostly derived by circulating monocyte which are recruited to the tumour
bed by the secretion from tumour cells and the other cells of the tumour microenvironment of
inflammatory cytokines such as M‐CSF/CSF‐1, SDF‐1/CCL12 and MCP‐1/CCL2. M2 macro‐
phages then are able to secrete large amount of growth factors, such as EGF, HGF, bFGF,
inflammatory factors (such as COX2) and angiogenic factors, including VEGF and angiogenic
chemokines, which in turn all together promote progression of tumours (reviewed in [55, 57]).
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In general, higher densities of TAMs in tumours and overexpression of key stimulators of M2
differentiation are considered markers of poor prognosis in a number of cancers [55, 57]. TAMs
are associated with tumour progression and poor survival in CRC patients [58, 59], in line with
in vitro and in vivo studies showing that macrophages are able to promote survival and induce
proliferation of CRC cells via activation of Wnt pathway in CRC cells [60–62]. However, some
other studies have shown that macrophages actually exert a tumour‐suppressive activity in
CRC via direct inhibition of tumour cell proliferation and via production of chemokines that
attract T cells, stimulate proliferation of allogeneic T cells and activate type‐1 T cells associated
with anti‐tumour immune responses [63]. In CRC, the role of macrophages may be ultimately
context and stage dependent with implications for the design of future therapies aiming to
target these cells.
8. Immune therapy in CRC
Given the complexity of the immune microenviroment and immune‐cell composition of CRC,
targeting this type of cancer via novel immunotherapies has been proved challenging.
However, as described in the following paragraphs, recent advanced in the immunotherapy
drug‐development together with a better understanding of the genetic basis of immune
stimulation have finally lead to the proof of concept demonstration that immunotherapy may
represent an important therapeutic tool in the treatment of CRC.
9. Immune‐cytokine therapy in CRC
Non‐specific immunotherapy utilising cytokines such as interferon (IFN), interleukins and
granulocyte macrophage colony‐stimulating factor (GM‐CSF) have been studied because of
the potential ability to modulate and promote host immunity against tumour antigens. A Phase
II trial of 29 patients with metastatic CRC using gemcitabine, oxaliplatin and 5‐fluorouracil
(GOLF) in combination with IL‐2 and GM‐CSF immune adjuvant regimen (GOLFIG) yielded
promising results, with an overall response rate of 56.5%, disease control rate of 96% and
median time to progression of 12.5 months [64]. A Phase III study comparing the GOLFIG
regimen against the control arm of FOLFOX‐4 in first line treatment of metastatic CRC was
terminated early due to poor recruitment into the control arm. However, the experimental arm
did show superiority in Progression Free Survival and Overall Response Rate with a trend
towards improvement of overall survival; this trial does provide proof‐of‐concept that
GOLFIG chemoimmunotherapy may represent a novel reliable option for first‐line treatment
of metastatic CRC [65].
10. Vaccines as therapeutic tools in CRC
Vaccine‐based therapy can be delivered as whole‐tumour‐cell vaccines, peptide vaccines, viral
vector vaccines or dendritic call vaccines, each with its inherent advantages and disadvantages
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(reviewed in [66, 67]). Overall in the treatment of CRC, there have been only small Phase I and
Phase II studies with suggestions that vaccines may have a role in the adjuvant setting, and
limited efficacy in metastatic disease. [68].
11. Rationale of checkpoint receptor pathway as a target in colorectal cancer
Immune checkpoints refer to a very complex and articulated series of inhibitory pathways that
intricate into the immune system and that are crucial for regulating self‐tolerance and modu‐
lating the duration and extent of physiological immune responses in peripheral tissues in order
to avoid excessive immune‐activation and subsequent collateral tissue damage (Figure 2) [69].
It is now well established that tumour cells can co‐opt certain immune‐checkpoint pathways;
this represents a novel and important mechanism of immune resistance, particularly against
T cells that are specific for tumour antigens. Consequently, the blockade of immune check‐
points is able to unleash T‐cell–mediated anti‐tumour immune response in a potent and
sometime curative way [69].
Figure 2. Immune checkpoint and immunosuppression in CRC. Immune checkpoints activate inhibitory pathways in
T cell that ultimately lead to T‐cell–mediated immunity suppression. Tumour cells can co‐opt these immune‐check‐
point pathways thus leading to T‐cell exhaustion and tumour immunotolerance.CTLA4: cytotoxic T‐lymphocyte‐asso‐
ciated antigen 4; PD1: programmed cell death protein 1; TIM3: T‐cell membrane protein 3; LAG3: lymphocyte
activation gene 3; BTLA: B‐ and T‐lymphocyte attenuator; VISTA: V‐domain Ig suppressor of T‐cell activation.
The two immune‐checkpoint receptors that have been most studied in the context of clinical
cancer immunotherapy, cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4; also known as
CD152) and programmed cell death protein 1 (PD1; also known as CD279) are both inhibitory
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receptors and have both shown to be appropriate targets (Figure 2). Importantly, several other
checkpoint immune pathways have recently emerged to be additional targets for the devel‐
opment of new immunotherapy drugs mostly in preclinical studies (Figure 2); these include
lymphocyte activation gene 3 (LAG3; also known as CD223), 2B4 (also known as CD244), B‐
and T‐lymphocyte attenuator (BTLA; also known as CD272), T‐cell membrane protein 3 (TIM3;
also known as HAVcr2), adenosine A2a receptor (A2aR) to name a few [70].
Programmed cell death 1 is a Type I transmembrane protein, which belongs to the CD28 family
[71]. PD‐1 is expressed on activated and exhausted T and B cells and has two ligands PD‐L1
and PD‐L2. Importantly, PD‐L1 is not expressed on normal epithelial tissues, but can aber‐
rantly be expressed on a variety of solid tumours [72]. On the other hand, PD‐L2 is more
broadly expressed on normal healthy tissues. Binding of PD‐L1 to PD‐1 reduces cytokine
production and activation of the target T cells, leading to an immunosuppressive microenvir‐
onment.
Clinical trials targeting PD‐1/PD‐L1 pathway to overcome tumour‐associated immune
suppression have shown promising results for a variety of solid tumours. Checkpoint inhibitor
immunotherapy is currently FDA‐approved for the treatment of melanoma, kidney cancer and
NSCLC. However, it has been shown active in many other types of solid, including gastric,
ovarian cancer, and bladder cancer, and hematologic cancers, particularly Hodgkin lymphoma
[73–76]. It is currently unclear what determines response to this type of treatment and this is
an area of active research giving the costs and the potential toxicity associated with these
treatments.
The accumulation of somatic mutations accompanies the initiation and progression of most
cancers conferring to the tumour cells unrestricted proliferative capacity [77]. The analysis of
cancer genomes has revealed that tumour mutational landscapes [78] are extremely variable
among patients, among different tumours from the same patient and even among the different
regions of a single tumour. Two separate papers have recently shown that response to
checkpoint inhibitors, i.e., anti‐CTL4 and anti‐PDL1 Ab, critically depend on the mutational
load of the specific tumours. The first study by Snyder et al. [79] found that mutational load
associates with exceptional response to the anti‐CTLA‐4 Ab ipilimumab in melanoma patients.
Using genome‐wide somatic neoepitope analysis and patient‐specific HLA‐typing, they
identified candidate tumour neoantigens for each patient predicted to be able to activate a T‐
cell response in anti‐CTLA‐4 treated patients.
Interestingly, the probability for a tumour to carry such neoantigens was dependent on the
mutational load of the specific tumour, as it was the probability to respond to anti‐CTLA‐4 Ab.
Similar results were obtained in NSCLC patients treated with pembrolizumab, an antibody‐
targeting PD‐1 [80]. A higher non‐synonymous mutation burden in tumours was associated
with improved objective response, durable clinical benefit and progression‐free survival.
Therapeutic benefit in these patients correlated with the molecular smoking signature, higher
neoantigen burden and DNA repair pathway mutations. All these factors were associated with
increased mutation burden [80].
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Both studies suggest for the first time a genomic‐based mechanism to the response to novel
immunotherapy drugs that can potentially help with designing rational combination treat‐
ments, i.e., DNA‐damaging agents plus immune‐checkpoint inhibitors.
12. PD1/PDL1—immune‐checkpoint inhibitors
In unselected colon cancer, the response to immune‐checkpoint inhibitors has shown limited
efficacy [73]. In tumours that have shown response, predictive markers to checkpoint inhibi‐
tion are being evaluated—with microsatellite insufficiency (MSI) or mismatch‐repair (MMR)
status being the most promising thus far [81].
Pembrolizumab (MK‐3475)—a highly selective humanised IgG4 monoclonal antibody that
blocks the interaction of PD‐1 with its ligands PD‐L1 and PD‐L2—has undergone extensive
testing in multiple tumour types. In the KEYNOTE‐028 study—a multicohort, Phase Ib trial of
pembrolizumab for programmed death‐ligand 1 (PD‐L1) positive advanced solid tumours;
there were 156 screened patients with advanced colorectal cancer, with 33 (21%) of these being
PD‐L1 positive and 23 went on to receive treatment. Although the safety profile was acceptable
with only one patient experiencing a grade ≥3 treatment‐related adverse events with elevated
bilirubin; it was felt there was overall minimal anti‐tumour activity. One patient who had
microsatellite instability high disease experienced a partial response, with four patients (17%)
having the best response of stable disease, and progressive disease in 16 patients (70%) [82].
The initial Phase I study of anti‐PD‐1 antibody nivolumab included 17 colorectal patients, who
were heavily pre‐treated; the majority of these patients had PD‐L1 negative tumours and thus
overall, this study showed limited clinical efficacy [83]. However, one patient with colorectal
cancer treated with five doses in this study experienced a complete response at 6 months, which
was ongoing after 3 years; it was noted that the patient's tumour was MSI‐high, and evidence
of PD‐L1 expression by infiltrating macrophages and lymphocytes [84].
Based on the previous reports associating mutational load to response to checkpoint inhibitors,
Le et al. hypothesised that mismatch repair–deficient tumours and mismatch repair (MMR)–
deficient tumours are more responsive to PD‐1 blockade than are MMR‐proficient tumours.
A Phase II study of 41 patients evaluating the clinical activity of pembrolizumab in metastatic
carcinoma with or without MMR‐deficiency showed hazard ratios for disease progression or
death (0.10; 95% CI, 0.03–0.37; P < 0.001) and for death (0.22; 95% CI, 0.05–1.00; P = 0.05) that
favoured patients with mismatch repair‐deficient colorectal cancer [85]. Thus, ongoing studies
are exploring this particular subset.
The KEYNOTE‐164 study (NCT02460198) is a Phase II study currently recruiting patients with
previously treated locally advanced unresectable or metastatic mismatched repair‐deficient or
MSI‐high colorectal carcinoma to assess efficacy of pembrolizumab monotherapy [85]. In the
same patient population of MSI‐high colorectal cancers, the Phase III KEYNOTE‐177
(NCT02563002) study will compare pembrolizumab monotherapy against standard of care
chemotherapy in first line treatment of advanced CRC [86].
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Regarding anti‐PD‐L1 compounds, atezolizumab (MPDL3280A) has shown activity in Phase
I studies—with one of four patients with colorectal cancer having a durable partial response
[87]. In the Phase Ib study of atezolizumab in combination with bevacizumab in refractory
metastatic CRC, and that of atezolizumab and bevacizumab with FOLFOX in the oxaliplatin
naïve population, this confirmed acceptable safety and clinical activity—unconfirmed ORR
8% (1/13) and 44% (8/18) in the two arms respectively [88]. However, the Phase I study of
BMS936559, which included 18 colorectal patients showed no response in this tumour type
[89]. There are ongoing studies with other anti‐PD‐L1 compounds including durvalumab/
MEDI4736 (NCT01693562) and avelumab (NCT01772004).
13. Anti‐CTLA4 Therapy
Tremilimumab, a fully human immunoglobulin (Ig) G2 monoclonal antibody that blocks
inhibitory signalling from CTLA4 was studied as monotherapy treatment in a Phase II single
arm study, of 47 patients with refractory metastatic CRC. Tremelimumab was intended to be
administered every 90 days. Clinical activity was unable to be demonstrated, with 43 of 45
evaluable patients unable to receive a second dose—with a median duration on study of 2.3
months [90]. However, a Phase I combination study of tremelimumab with durvalumab
(NCT01975831) is ongoing; and ipilimumab is also being studied in combination with
nivolumab (NCT02060188).
14. Other immune‐checkpoint inhibitors
In MSI‐high colon cancers, it has been shown that up‐regulation of PD‐1, PD‐L1, CTLA‐4, LAG‐
3 and IDO immune checkpoints enables evasion from Th1 response [91]. As described, PD‐L1,
PD‐1, CTLA‐4 have been and are being investigated in the treatment of CRC. Anti‐LAG‐3
monoclonal antibodies (BMS‐986016), alone and in combination with nivolumab are also being
evaluated (NCT01968109).
15. Other combined immunotherapy strategies
As there has been limited efficacy from current immunotherapy strategies, it has been
proposed that combination of immunotherapy with conventional chemotherapy, radiothera‐
py and targeted agents should be trialled [92]. The use of DNA damaging agents may increase
the mutation burden, thus increase the efficacy of checkpoint inhibition.
16. Conclusion
Advanced CRC remains inevitably lethal despite optimal management, thus novel therapeutic
approaches are urgently needed. Immunotherapy, particularly novel immune‐checkpoint
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inhibitors, is transforming the therapeutic landscape of many types of cancer. Although in
CRC the clinical data have been disappointing so far, this is probably due to the lack of
knowledge of biomarkers/clinical features that can allow us the optimal selection of patients
likely to respond to the specific immunotherapies. This has been proved by the identification
of MMR status as a specific marker of response to anti‐PD1/PDL1 treatment in CRC. In the
future, a deeper understanding of immunobiology of CRC together with the development of
novel immunotherapeutic agents will surely lead to new successful treatments for advanced
CRC patients. This will be followed by further studies of combination of novel immunothera‐
pies together with the present standard of care, i.e., surgery, chemotherapy and target therapies
that will additionally improve the prognosis of advanced metastatic CRC.
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